CD36 and acute myeloid leukemia: Hence, potential protecting effect from natural levels of albumin surrounding AML cells in blood and bone marrow must be taken into consideration for targeting CD36 in patients, and therefore there is a need to improve the affinity of SMS121 for CD36 before it can be judged as a lead compound and validated for AML treatment.